eTheRNA immunotherapies NV

Activities: Pharmaceutical

Trending Articles

  1. Knowledge and adaptability drive successful pharmaceutical outsourcing partnerships Third-party contract manufacturers and packers play an increasingly prominent role in the pharmaceutical sector, helping companies to both navigate the complexities of the...
  2. dsm-firmenich showcases excipient and sustainability solutions at CPHI Milan The company will present its range of solutions designed to boost patient compliance, while also exhibiting its pharma-grade CBD ingredient
  3. Roche's cancer immunotherapy Tecentriq Hybreza bags FDA approval The drug first and only subcutaneous PD-(L)1 inhibitor available for patients with certain types of lung, skin, liver and soft tissue cancers
  4. Reducing a chemical manufacturing plant’s energy demand The industrial sector has historically associated energy efficiency with making incremental improvements to thermal utility systems. Typical gains and carbon dioxide reductions...
  5. Causes and solutions for dark spots in tablet manufacturing Natoli Engineering examines the causes and solutions for dark spots that can halt production

Upcoming event

Boston Biotech Week

23-26 September, 2024 | Convention and exhibition | Boston, US See all

Related Content

Manufacturing

etherna appoints Antonin de Fougerolles as new Chairperson

Tony has extensive experience in the development of novel therapeutic modalities, such as RNAis and modified mRNAs for vaccinations
Research & Development

etherna and Hasselt University collaborate to develop mRNA-based therapies for autoimmune disease

The collaboration will aim to develop treatments for multiple sclerosis, and is backed by Flanders Innovation & Entrepreneurship (VLAIO)
Manufacturing

etherna appoints Shelly West as Business Development Director, US

Shelly arrives from Cellpoint Biosciences and will be in charge of expanding etherna's US customer base
Ingredients

LNP formulation improves mRNA vaccine efficacy and tolerability

S-Ac7-DOG encapsulated mRNA demonstrated markedly higher transfection, lower reactogenicity, and higher accumulation in the vaccine draining lymph nodes
Research & Development

Almirall and etherna to develop mRNA-based therapies in medical dermatology

The collaboration leverages etherna’s proprietary mRNA and lipid nanoparticle (LNP) technology with Almirall’s expertise in the dermatology space
Manufacturing

eTheRNA Manufacturing announces LNP development service

The service uses the company’s proprietary lipid libraries and proprietary formulations to facilitate targeted delivery and tailored biodistribution solutions
Research & Development

eTheRNA announces mRNA research agreement with Merck

The ongoing pandemic has underlined the capability for mRNA vaccines as a therapeutic modality
Subscribe now